Scarica l'app Stockscreener
3.41
1.19%
0.04
Precedente Chiudi:
$3.37
Aprire:
$3.32
Volume 24 ore:
391.32K
Relative Volume:
1.10
Capitalizzazione di mercato:
$186.05M
Reddito:
$163.78M
Utile/perdita netta:
$25.88M
Rapporto P/E:
5.2462
EPS:
0.65
Flusso di cassa netto:
$-28.66M
1 W Prestazione:
-6.32%
1M Prestazione:
-16.42%
6M Prestazione:
-41.41%
1 anno Prestazione:
-65.59%
Intervallo 1D:
$3.29
$3.52
Intervallo di 1 settimana:
$3.26
$3.785
Portata 52W:
$3.26
$9.72
Voyager Therapeutics Inc Stock (VYGR) Company Profile
Nome
Voyager Therapeutics Inc
Settore
Industria
Telefono
857-259-5340
Indirizzo
75 HAYDEN AVENUE, LEXINGTON, MA
Confronta VYGR con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VYGR
Voyager Therapeutics Inc
|
3.41 | 186.05M | 163.78M | 25.88M | -28.66M | 0.65 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.49 | 124.48B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
625.60 | 67.45B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
583.62 | 35.60B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
266.83 | 34.53B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
274.78 | 29.15B | 3.81B | -644.79M | -669.77M | -6.24 |
Voyager Therapeutics Inc Stock (VYGR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-01-10 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-12-02 | Iniziato | Citigroup | Buy |
| 2024-11-29 | Ripresa | Wedbush | Outperform |
| 2024-10-16 | Iniziato | Leerink Partners | Outperform |
| 2024-03-26 | Iniziato | Guggenheim | Buy |
| 2024-03-19 | Iniziato | H.C. Wainwright | Buy |
| 2024-03-07 | Iniziato | Citigroup | Buy |
| 2024-01-02 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-05-10 | Iniziato | Truist | Buy |
| 2023-03-10 | Iniziato | Oppenheimer | Outperform |
| 2021-10-07 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2021-02-26 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2021-02-03 | Downgrade | BTIG Research | Buy → Neutral |
| 2021-02-03 | Downgrade | Wedbush | Outperform → Neutral |
| 2020-12-24 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2020-12-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2020-11-11 | Downgrade | Oppenheimer | Outperform → Perform |
| 2020-11-10 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2020-11-10 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2020-03-19 | Iniziato | The Benchmark Company | Buy |
| 2020-02-06 | Iniziato | Oppenheimer | Outperform |
| 2018-11-15 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2018-09-10 | Ripresa | BTIG Research | Buy |
| 2018-09-10 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2018-06-04 | Iniziato | H.C. Wainwright | Buy |
| 2018-03-12 | Downgrade | Evercore ISI | Outperform → In-line |
| 2018-03-12 | Downgrade | Wedbush | Outperform → Neutral |
| 2018-02-02 | Iniziato | Morgan Stanley | Overweight |
| 2017-11-28 | Ripresa | Piper Jaffray | Overweight |
| 2017-10-31 | Iniziato | Robert W. Baird | Outperform |
| 2017-10-27 | Iniziato | Canaccord Genuity | Buy |
| 2017-10-23 | Reiterato | Stifel | Buy |
| 2017-10-12 | Iniziato | Raymond James | Outperform |
| 2017-08-17 | Iniziato | Evercore ISI | Outperform |
| 2017-07-28 | Ripresa | Stifel | Buy |
Mostra tutto
Voyager Therapeutics Inc Borsa (VYGR) Ultime notizie
Voyager Therapeutics stock hits 52-week low at $3.54 By Investing.com - Investing.com Philippines
Voyager Therapeutics stock hits 52-week low at $3.54 - Investing.com
Voyager Therapeutics Presents Promising Tau-Targeting Gene Therapy And Antibody Data At AD/PD 2025 - Nasdaq
Voyager reveals promising Alzheimer’s therapy data By Investing.com - Investing.com Australia
Voyager Presents Robust Preclinical Data from Tau Targeting Gene Therapy and Antibody Programs at AD/PD™ 2025 - GlobeNewswire
New Alzheimer's Breakthrough: Single-Dose Gene Therapy Slashes Tau Levels by 73% - Stock Titan
Voyager Therapeutics at Virtual CNS Forum: Strategic Insights on Neurotherapeutics - Investing.com UK
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Voyager Therapeutics, Inc.VYGR - PR Newswire
Voyager Therapeutics' (VYGR) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
Canaccord Genuity Group Cuts Voyager Therapeutics (NASDAQ:VYGR) Price Target to $12.00 - Armenian Reporter
Voyager Therapeutics (NASDAQ:VYGR) Earns “Buy” Rating from HC Wainwright - Defense World
Voyager Therapeutics COO Robin Swartz sells $30,927 in stock - MSN
Cantor Fitzgerald Reaffirms “Overweight” Rating for Voyager Therapeutics (NASDAQ:VYGR) - Defense World
Voyager Therapeutics (VYGR) Reports Q4 Loss, Misses Revenue Estimates - MSN
H.C. Wainwright maintains $30 target on Voyager Therapeutics stock By Investing.com - Investing.com Canada
Voyager Therapeutics’ Earnings Call Highlights Promising Future - TipRanks
A Glimpse Into The Expert Outlook On Voyager Therapeutics Through 4 Analysts - Benzinga
Voyager Therapeutics stock hits 52-week low at $3.67 - Investing.com
Voyager Therapeutics stock hits 52-week low at $3.67 By Investing.com - Investing.com Australia
Voyager Therapeutics, Inc. (NASDAQ:VYGR) Q4 2024 Earnings Call Transcript - Insider Monkey
Voyager Therapeutics price target lowered to $10 from $12 at Wells Fargo - TipRanks
Voyager Therapeutics Inc earnings missed by $0.22, revenue fell short of estimates - Investing.com
Earnings call transcript: Voyager Therapeutics Q4 2024 sees stock dip post-earnings - Investing.com Australia
Voyager Therapeutics Reports 2024 Financial Results and Progress - TipRanks
Voyager Therapeutics: Strong Financials and Promising Pipeline Drive Buy Rating - TipRanks
Earnings call transcript: Voyager Therapeutics Q4 2024 sees stock dip post-earnings By Investing.com - Investing.com South Africa
Voyager Therapeutics: Q4 Earnings Snapshot - mySA
Voyager Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
VOYAGER THERAPEUTICS Earnings Results: $VYGR Reports Quarterly Earnings - Nasdaq
Voyager Therapeutics, Inc. SEC 10-K Report - TradingView
Voyager Therapeutics Reports Fourth Quarter and Full Year 2024 Financial and Operating Results - TradingView
Voyager Reports Fourth Quarter and Full Year 2024 Financial and Operating Results - GlobeNewswire
Voyager Reports Fourth Quarter and Full Year 2024 Financial and Operating Results - GlobeNewswire Inc.
VOYAGER THERAPEUTICS Earnings Preview: Recent $VYGR Insider Trading, Hedge Fund Activity, and More - Nasdaq
Rhumbline Advisers Increases Stake in Voyager Therapeutics, Inc. (NASDAQ:VYGR) - Defense World
Voyager Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire
Voyager Therapeutics Announces Fourth Quarter 2024 Conference Call and Webcast - GlobeNewswire
John Stankey Updates Shareholders at Morgan Stanley Technology, Media & Telecom Conference on March 4 - The Globe and Mail
New tau candidates, including an RNA therapy from Voyager, drive a multi-pronged Alzheimer’s approach - PharmaVoice
When Will Voyager Therapeutics Reveal Its Latest Neurogenetic Medicine Progress? - StockTitan
Voyager Therapeutics (NASDAQ:VYGR) Given “Buy” Rating at HC Wainwright - Defense World
Voyager Therapeutics Reports Positive Trial Results From Alzheimer's Disease Treatment - Marketscreener.com
Voyager Therapeutics Reports Positive Data From Single Ascending Dose Study Of VY7523 - Nasdaq
Voyager Therapeutics Reports Positive Topline Data for VY7523 in Alzheimer’s Disease Trials - Nasdaq
Voyager Reports Positive Topline Data for Single Ascending Dose (SAD) Trial of Anti-Tau Antibody VY7523 and Initiates Multiple Ascending Dose (MAD) Trial in Alzheimer's Disease - The Manila Times
Voyager Reports Positive Topline Data for Single Ascending - GlobeNewswire
Can Voyager's Anti-Tau Antibody Break Through in Alzheimer's Treatment? Phase 1 Results Show Promise - StockTitan
Voyager Therapeutics, Inc. (NASDAQ:VYGR) Given Consensus Rating of “Buy” by Brokerages - Defense World
Voyager Therapeutics stock hits 52-week low at $4 - Investing.com India
Voyager Therapeutics stock hits 52-week low at $4 By Investing.com - Investing.com South Africa
Voyager Therapeutics Inc Azioni (VYGR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.00%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):